New injection could ease sleep apnea and aid weight loss
NCT ID NCT07501832
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an injection called GZR18 in 140 obese adults with moderate-to-severe obstructive sleep apnea who already use a breathing machine (PAP). The goal is to see if the drug improves breathing during sleep, reduces weight, and boosts quality of life compared to a placebo. It is a Phase 3 trial, meaning it is in the final stages before possible approval.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GZR18 injection
What this could lead to
If it works, this could offer a new treatment that reduces sleep apnea severity and helps with weight loss in obese patients.
What could go wrong
This is an early-stage Phase 3 trial with only 140 participants, so results may not apply to everyone. The drug may cause side effects or not improve sleep apnea significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE SLEEP APNEA (OSA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gan & Lee Pharmaceuticals
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••